These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37047564)

  • 1. Use of Nanostructured Silica SBA-15 as an Oral Vaccine Adjuvant to Control
    Storino GY; Petri FAM; Mechler-Dreibi ML; Aguiar GA; Toledo LT; Arruda LP; Malcher CS; Martins TS; Montassier HJ; Sant'Anna OA; Fantini MCA; de Oliveira LG
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047564
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral vaccination of piglets against Mycoplasma hyopneumoniae using silica SBA-15 as an adjuvant effectively reduced consolidation lung lesions at slaughter.
    Mechler-Dreibi ML; Almeida HMS; Sonalio K; Martines MAC; Petri FAM; Zambotti BB; Ferreira MM; Storino GY; Martins TS; Montassier HJ; Sant'Anna OA; Fantini MCA; de Oliveira LG
    Sci Rep; 2021 Nov; 11(1):22377. PubMed ID: 34789792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy evaluation of a novel oral silica-based vaccine in inducing mucosal immunity against Mycoplasma hyopneumoniae.
    Ferreira GC; Sanches TVC; Mechler-Dreibi ML; Almeida HMS; Storino GY; Sonalio K; Petri FAM; Martins TS; Cides da Silva LC; Montassier HJ; Sant'Anna OA; Fantini MCA; de Oliveira LG
    Res Vet Sci; 2023 May; 158():141-150. PubMed ID: 37004428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of effects of a single dose of MHYOSPHERE® PCV ID with three commercial porcine vaccine associations against Mycoplasma hyopneumoniae (Mhyo) and porcine circovirus type 2 (PCV2) on piglet growth during the nursery period under field conditions.
    Puig A; Bernal I; Sabaté D; Ballarà I; Montané J; Nodar L; Angelats D; Jordà R
    Vet Res Commun; 2022 Dec; 46(4):1167-1173. PubMed ID: 35829861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of a sIgA-ELISA method for differentiation of Mycoplasma hyopneumoniae infected from vaccinated pigs.
    Bai Y; Gan Y; Hua LZ; Nathues H; Yang H; Wei YN; Wu M; Shao GQ; Feng ZX
    Vet Microbiol; 2018 Sep; 223():86-92. PubMed ID: 30173757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different local, innate and adaptive immune responses are induced by two commercial
    Beuckelaere L; Haspeslagh M; Biebaut E; Boyen F; Haesebrouck F; Krejci R; Meyer E; Gleerup D; De Spiegelaere W; Devriendt B; Maes D
    Front Immunol; 2022; 13():1015525. PubMed ID: 36569943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responses of a chimaeric protein vaccine containing Mycoplasma hyopneumoniae antigens and LTB against experimental M. hyopneumoniae infection in pigs.
    Marchioro SB; Sácristan Rdel P; Michiels A; Haesebrouck F; Conceição FR; Dellagostin OA; Maes D
    Vaccine; 2014 Aug; 32(36):4689-94. PubMed ID: 24909331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination of piglets up to 1 week of age with a single-dose Mycoplasma hyopneumoniae vaccine induces protective immunity within 2 weeks against virulent challenge in the presence of maternally derived antibodies.
    Wilson S; Van Brussel L; Saunders G; Runnels P; Taylor L; Fredrickson D; Salt J
    Clin Vaccine Immunol; 2013 May; 20(5):720-4. PubMed ID: 23486417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic and local immune response in pigs intradermally and intramuscularly injected with inactivated Mycoplasma hyopneumoniae vaccines.
    Martelli P; Saleri R; Cavalli V; De Angelis E; Ferrari L; Benetti M; Ferrarini G; Merialdi G; Borghetti P
    Vet Microbiol; 2014 Jan; 168(2-4):357-64. PubMed ID: 24332702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of three innovative bacterin vaccines against experimental infection with Mycoplasma hyopneumoniae.
    Matthijs AMF; Auray G; Boyen F; Schoos A; Michiels A; García-Nicolás O; Barut GT; Barnier-Quer C; Jakob V; Collin N; Devriendt B; Summerfield A; Haesebrouck F; Maes D
    Vet Res; 2019 Nov; 50(1):91. PubMed ID: 31703726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of challenge of pigs previously immunised with inactivated vaccines containing homologous and heterologous Mycoplasma hyopneumoniae strains.
    Villarreal I; Vranckx K; Calus D; Pasmans F; Haesebrouck F; Maes D
    BMC Vet Res; 2012 Jan; 8():2. PubMed ID: 22225838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 3 vaccination strategies against porcine reproductive and respiratory syndrome virus,
    Jeong J; Kang I; Kim S; Park KH; Park C; Chae C
    Can J Vet Res; 2018 Jan; 82(1):39-47. PubMed ID: 29382967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo and in vitro comparisons of spray-drying and solvent- evaporation preparation of microencapsulated Mycoplasma hyopneumoniae for use as an orally administered vaccine for pigs.
    Lin JH; Pan MJ; Liao CW; Weng CN
    Am J Vet Res; 2002 Aug; 63(8):1118-23. PubMed ID: 12171164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Mycoplasma hyopneumoniae vaccination before and at weaning against experimental challenge infection in pigs.
    Arsenakis I; Panzavolta L; Michiels A; Del Pozo Sacristán R; Boyen F; Haesebrouck F; Maes D
    BMC Vet Res; 2016 Mar; 12():63. PubMed ID: 27025924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination of piglets at 1 week of age with an inactivated Mycoplasma hyopneumoniae vaccine reduces lung lesions and improves average daily gain in body weight.
    Wilson S; Van Brussel L; Saunders G; Taylor L; Zimmermann L; Heinritzi K; Ritzmann M; Banholzer E; Eddicks M
    Vaccine; 2012 Dec; 30(52):7625-9. PubMed ID: 23084853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of different adjuvant formulations on the immunogenicity and protective effect of a live Mycoplasma hyopneumoniae vaccine after intramuscular inoculation.
    Xiong Q; Wei Y; Xie H; Feng Z; Gan Y; Wang C; Liu M; Bai F; Xie F; Shao G
    Vaccine; 2014 Jun; 32(27):3445-51. PubMed ID: 24731810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives for improvement of Mycoplasma hyopneumoniae vaccines in pigs.
    Maes D; Boyen F; Devriendt B; Kuhnert P; Summerfield A; Haesebrouck F
    Vet Res; 2021 May; 52(1):67. PubMed ID: 33964969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of recombinant Mycoplasma hyopneumoniae P97/P102 paralogs formulated with selected adjuvants as vaccines against mycoplasmal pneumonia in pigs.
    Woolley LK; Fell SA; Gonsalves JR; Raymond BB; Collins D; Kuit TA; Walker MJ; Djordjevic SP; Eamens GJ; Jenkins C
    Vaccine; 2014 Jul; 32(34):4333-41. PubMed ID: 24930717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between single-dose Mycoplasma hyopneumoniae and porcine reproductive and respiratory syndrome virus vaccines on dually infected pigs.
    Park SJ; Seo HW; Park C; Chae C
    Res Vet Sci; 2014 Jun; 96(3):516-22. PubMed ID: 24702900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycoplasma hyopneumoniae: from disease to vaccine development.
    Simionatto S; Marchioro SB; Maes D; Dellagostin OA
    Vet Microbiol; 2013 Aug; 165(3-4):234-42. PubMed ID: 23680109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.